Altered emotional experiences attributed to antipsychotic medications - A potential link with estimated dopamine D2 receptor occupancy

Psychiatry Research
Irene M LakoRichard Bruggeman

Abstract

Altered emotional experiences in response to antipsychotics may increase the burden of disease in patients with schizophrenia. In a large cross-sectional study, patients with schizophrenia completed the Subjects Reaction to Antipsychotics questionnaire (SRA) to assess whether they attributed altered emotional experiences (flattened affect or depressive symptoms) to their antipsychotics. Association with antipsychotic D2 receptor affinity and occupancy was examined using logistic regression. We compared antipsychotic-attributed emotional experiences between patients using antipsychotic monotherapy and combination therapy. Of the 1298 included patients, 23% attributed flattened affect to their antipsychotics and 16% attributed depressive symptoms to their antipsychotics, based on the SRA. No differences were observed between antipsychotics in patients on monotherapy. We discuss that within these patients' relatively low dose range, altered emotional experiences did not appear to relate to the level of D2 receptor affinity of antipsychotic monotherapy. Patients using antipsychotic combination therapy (22%) were more likely to attribute depressive symptoms to their antipsychotics than patients using antipsychotic monotherapy (OR [9...Continue Reading

References

Sep 1, 1978·Archives of General Psychiatry·T Van Putten, R P May
Jun 1, 1992·Psychiatry Research·J P LindenmayerR Plutchik
Aug 31, 2000·The American Journal of Psychiatry·S G Siris
Jun 5, 2001·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R M ProcyshynB Thompson
Oct 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·L VorugantiA G Awad
Jun 27, 2002·Schizophrenia Research·Rodrigo A BressanLyn S Pilowsky
Oct 3, 2002·The British Journal of Psychiatry : the Journal of Mental Science·H M Jones, L S Pilowsky
Jan 14, 2003·The Journal of Clinical Psychiatry·Diana O Perkins
Apr 7, 2005·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller
Jul 5, 2005·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller
Dec 1, 2005·International Clinical Psychopharmacology·Hugo A WoltersRobert J van den Bosch
May 24, 2007·International Clinical Psychopharmacology·Corrado BarbuiLuigi Grassi
Feb 7, 2008·The Cochrane Database of Systematic Reviews·V A Furtado, V Srihari
Sep 6, 2008·Progress in Brain Research·Herbert Y Meltzer, Mei Huang
Dec 1, 2009·The Psychiatric Clinics of North America·Robert R Conley
Feb 5, 2011·European Psychiatry : the Journal of the Association of European Psychiatrists·I M LakoC J Slooff
May 26, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Janusz K RybakowskiUNKNOWN EUFEST Study Group
Aug 21, 2013·Journal of Clinical Psychopharmacology·Irene M LakoKatja Taxis
Jun 21, 2014·Journal of Clinical Psychopharmacology·Irene M LakoKatja Taxis
Aug 3, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Janusz K RybakowskiUNKNOWN EUFEST Study Group
Sep 17, 2014·Nordic Journal of Psychiatry·Niko SeppäläOlli Kampman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here